Mesenchymal Stem Cells in Asthma

Akkoç, Tunç

doi:10.1007/5584_2019_460

Cited by 4 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, cell-based therapy seems to become a study spot and may become a novel treating approach. Mesenchymal stem cells (MSCs) are considered to have the capacity for self-renewal and exist in adipose tissue, umbilical cord blood, bone marrow, and so on [ 83 ]. BMMSC was isolated from bone marrow, which was widely used for its abundant source and easy availability, showing therapeutic potential in many immune and inflammatory diseases, such as COVID-19, acute refractory graft-vs-host disease (GVHD), chronic obstructive pulmonary disease (COPD), and asthma [ 84 ].…”

Section: Bone Marrow Mesenchymal Stem Cells-derived Exosome ( ...mentioning

confidence: 99%

Promising Therapeutic Functions of Bone Marrow Mesenchymal Stem Cells Derived-Exosome in Asthma

Yan

Wang

Tong

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

Asthma is a chronic inflammatory disturbance of the airways in which many cells and cellular elements are involved. Wheezing, breathlessness, chest tightness, and coughing, especially at night or in the early morning, are typical symptoms of asthma. At present, inhaled corticosteroid (ICS) and long-acting β-agonists (LABAs) are standard treatments for regular management. Oral corticosteroids (OCSs) were recommended for controlling asthma exacerbation but only for a short-term treatment because of the side effects on organs. Biologic therapies have achieved exciting and notable effects in clinical treatment but are not applicable for all phenotypes of asthma. At present, some new approaches are under exploration to lessen side effects and improve curative effects. Studies have revealed that bone marrow mesenchymal stem cells (BMMSCs) hold various curative effects in asthma and may benefit in the long term with high safety. Extracellular vesicles (EVs) enriched in body fluid were characterized as subcomponents of extracellular vesicles and delivered carriers combined with genetic messages in vivo. The therapeutic potential of exosomes has become a research hotspot in many diseases. BMMSC-derived exosomes were considered as the dominant part of BMMSCs in cell-to-cell communications and playing curative effects. Points also hold that BMMSC-Exo could interfere with airway inflammation and airway remolding in asthma via modulating the immune response, regulating gene expression, adjusting the phenotype of macrophage, etc. However, BMMSC-Exo still lacked more clinical trials for evaluating the effects on asthma, and the technology of extraction and purification still needs to be improved for wide use. This review aims to draw the relationship among asthma, BMMSC, and exosome, which may provide innovate ideas for treatment of asthma, and arouse attention about the curative potential of BMMSC-Exo.

show abstract

Section: Bone Marrow Mesenchymal Stem Cells-derived Exosome ( ...mentioning

confidence: 99%

Promising Therapeutic Functions of Bone Marrow Mesenchymal Stem Cells Derived-Exosome in Asthma

Yan

Wang

Tong

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Basically, they suppress T cell proliferation and regulate the balance of Th1 (autoimmunity related)/Th2 (allergic disease related). On the other hand, they regulate the immune response with T regulatory cells and control antigen presentation of dendritic cells (Akkoc 2019;Duman et al 2019;Genc et al 2019). All of these modulatory effects are important to control cytokine storm disease.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not

Akkoç

2020

Cell Biology and Translational Medicine, Volume 10

Self Cite

View full text Add to dashboard Cite

On December 31, 2019, novel SARS-CoV2 spread from Wuhan China to more than 200 territories around world and the World Health Organization declared a COVID-19 pandemic on January 30, 2020. At this time there is no particular therapy, drug or vaccine available to deal with COVID-19. Today actual data indicates that about 17% of closed COVID-19 cases died. Health care professionals, ministry of health in countries and the public are trying to read the runes to see when the COVID-19 pandemic will be over. Although mild cases of COVID-19 can be controlled with antiviral, anti-inflammatory and immunomodulatory treatment, severe cases may need intensive care unit support and ventilation. Cytokine storms cause high inflammatory responses and pneumonia in severe cases. Mesenchymal stem cells are immunomodulatory and they have regenerative capacity. In this sense, mesenchymal stem cells may improve the patient's clinical and immunological response to COVID-19.

show abstract

“…Increasing attention has been paid to the possibility of mesenchymal stem cells (MSCs) therapy in asthma patients (9,10). MSCs can exert immunomodulatory functions through the release of extracellular vesicles or cytokines (11), which makes MSCs possess potential regulatory functions for in ammatory diseases.…”

Section: Introductionmentioning

confidence: 99%

Umbilical cord mesenchymal stem cell alleviates asthma via Nrf2/HO-1/NF-κB signaling pathway

Yong

Lin

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Numerous previous studies have proved the immunomodulatory properties of mesenchymal stem cells (MSCs) especially for human umbilical cord mesenchymal stem cells (UC.MSCs) in the progression of asthma, but the action mechanism remains unclear.Methods In the present work, a rat asthma model induced by ovalbumin (OVA) was established to ascertain the effects of UC.MSCs treatment on inflammation, oxidative stress and airway remodeling. Additionally, both in rat asthma model and TGF-β-induced airway smooth muscle cells (ASMCs), the interaction of UC.MSCs with Nrf2/HO-1/NF-κB pathway was evaluated.Results We demonstrated that OVA-induced inflammation infiltration and the increase of cell counts of eosinophils, lymphocytes, and macrophages were dramatically reduced after UC.MSCs treatment. The downregulated expression of anti-oxidant genes (NQO1 and HO-1), and the reduced GSH levels caused by OVA challenge were restored following the treatment of UC.MSCs. Meanwhile, UC.MSCs also prohibited collagen deposition, suppressed goblet cell hyperplasia and decreased the levels of airway remodeling markers (α-SMA, TGF-β1, MMP9 and TIMP1) in asthma rat model. In in vitro experiments, TGF-β could facilitate the viability of ASMCs and restrain G1 cell cycle arrest, while UC.MSCs revised these changes. Additionally, treatment with UC.MSCs could significantly activate the expression of HO-1 and NRF2, but inhibit NF-κB levels in vivo and in vitro.Conclusions In a word, these findings indicated that UC.MSCs can alleviate asthma via Nrf2/HO-1/NF-κB signaling pathway, which provided a theoretical basis for asthma therapy in clinic.

show abstract

Mesenchymal Stem Cells in Asthma

Cited by 4 publications

References 52 publications

Promising Therapeutic Functions of Bone Marrow Mesenchymal Stem Cells Derived-Exosome in Asthma

Promising Therapeutic Functions of Bone Marrow Mesenchymal Stem Cells Derived-Exosome in Asthma

COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not

Umbilical cord mesenchymal stem cell alleviates asthma via Nrf2/HO-1/NF-κB signaling pathway

Contact Info

Product

Resources

About